Skip to main content
AUPH
NASDAQ Life Sciences

Officer Gregory Keenan Files Intent to Sell $54.1M in Aurinia Pharmaceuticals Shares

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$15.39
Mkt Cap
$1.979B
52W Low
$7.285
52W High
$16.88
52W Position info
111% above low
Off High info
8.8% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

AUPH has more than doubled off its 52-week low of $7.285.

Summary

An officer of Aurinia Pharmaceuticals intends to sell $54.1 million in shares, acquired through option exercise, representing a significant disposition.


Key Events · Ownership and Investor Activity · AUPH

  • Officer Files Intent to Sell Shares

    Gregory Keenan, an officer of Aurinia Pharmaceuticals, filed a Form 144 to sell 25,000 shares of common stock.

  • Significant Value of Intended Sale

    The proposed sale has an approximate market value of $54.1 million, representing about 2.73% of the company's market capitalization.

  • Shares Acquired via Option Exercise

    The shares to be sold were acquired through the exercise of options under a registered plan on the same day as the filing.


Analysis · AUPH · Life Sciences

Gregory Keenan, an officer of Aurinia Pharmaceuticals, has filed a Form 144 indicating an intent to sell approximately $54.1 million worth of common stock. This significant disposition, representing about 2.73% of the company's market capitalization, stems from the exercise of options under a registered plan. The substantial size of the intended sale by a current officer could be interpreted negatively by investors, suggesting a desire to monetize a large portion of their holdings.

How filings like this one have moved

In the 30 days to Sep 15, 2026, 40.7% of the 388 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.42%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AUPH was trading at $15.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $7.29 to $16.88. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AUPH - Latest Insights

AUPH
Aug 19, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $16.34
Real-time Price: $16.41 info
Change: +$0.070 (+0.43%) info
Market Cap: $2.183B info
AUPH
Aug 19, 2026, 4:07 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $16.57
Real-time Price: $16.41 info
Change: -$0.160 (-0.97%) info
Market Cap: $2.183B info
AUPH
Aug 06, 2026, 8:16 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $15.75
Real-time Price: $16.41 info
Change: +$0.660 (+4%) info
Market Cap: $2.183B info
AUPH
Aug 06, 2026, 8:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.85
Real-time Price: $16.41 info
Change: +$0.5614 (+4%) info
Market Cap: $2.183B info
AUPH
Aug 06, 2026, 8:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $15.75
Real-time Price: $16.41 info
Change: +$0.660 (+4%) info
Market Cap: $2.183B info